Literature DB >> 7874109

RET proto-oncogene mutations in French MEN 2A and FMTC families.

I Schuffenecker1, M Billaud, A Calender, B Chambe, N Ginet, C Calmettes, E Modigliani, G M Lenoir.   

Abstract

Constitutional mutations of the RET proto-oncogene have been identified in multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC) families. We sequenced RET exons 10 and 11 in 86 unrelated patients with an inherited predisposition to MTC (excluding MEN 2B). Germ-line mutations were identified in 93% of the MEN 2A families and 67% of the FMTC families tested. All were missense mutations affecting one of three cysteines in the extracellular domain of the RET tyrosine kinase receptor. The prevalence of phaeochromocytoma and hyperparathyroidism was significantly higher in families with a mutation of cysteine 634. These data confirm the preferential localisation of MEN 2A and FMTC associated mutations and the strong correlation between clinical manifestations and the position of RET mutation. Although direct sequencing of RET exons 10 and 11 allows the identification of a constitutional mutation in a large proportion of MEN 2A and FMTC families, our data sustain the existence of other MTC predisposing mutations elsewhere in RET coding or regulating region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7874109     DOI: 10.1093/hmg/3.11.1939

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

3.  Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.

Authors:  M F Erdogan; A Gürsoy; G Ozgen; M Cakir; F Bayram; R Ersoy; E Algün; B Cetinarslan; A Cömlekçi; P Kadioglu; M K Balci; I Yetkin; T Kabalak; G Erdogan
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

4.  Ret-proto-oncogene analysis in medullary thyroid carcinoma.

Authors:  D A O'Keeffe; A D Hill; K Sheahan; F Ryan; D Barton; R J Fitzgerald; E W McDermott; N J O'Higgins
Journal:  Ir J Med Sci       Date:  1998 Oct-Dec       Impact factor: 1.568

Review 5.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

Review 6.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 7.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

Review 8.  Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Authors:  Andreas Machens; Henning Dralle
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

9.  Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.

Authors:  Beatriz González-Yebra; María Elena Medrano; Alejandra Mantilla; Virginia Palma; Carmen Colin; Dulce María Hernández; José Tapia; Brian Dawson; Mauricio Salcedo
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 10.  Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.

Authors:  Andrea Frilling; Frank Weber; Carsten Tecklenborg; Christoph Erich Broelsch
Journal:  Langenbecks Arch Surg       Date:  2003-03-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.